Linnie Chang

Linnie is the Vice President of Finance at Genezen and leads the finance and accounting functions. She brings a wealth of industry experience to her role. Previously, she served as the Sr. Director of Finance at Orum Therapeutics, a clinical stage biotech company known for its novel class of protein degraders. Before that, she was the Controller at Arranta Bio, a leading CDMO for mRNA, from its inception in 2019 until its successful acquisition by Recipharm in February 2022. Linnie has also held positions at publicly traded bio-pharmaceutical companies during times of rapid growth and transformation, where she implemented processes to maximize efficiency and provide better financial visibility to internal and external stakeholders. Linnie is a Certified Public Accountant and began her career as an auditor with KPMG, where she worked with multinational SEC clients. She holds a Bachelor’s and Master’s degree in Accounting from the University of Massachusetts Amherst.